scholarly journals Proposal of RT-PCR–Based Mass Population Screening for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019)

2020 ◽  
Vol 22 (10) ◽  
pp. 1294-1299 ◽  
Author(s):  
Nikhil S. Sahajpal ◽  
Ashis K. Mondal ◽  
Allan Njau ◽  
Sudha Ananth ◽  
Kimya Jones ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Population Screening ◽  
Rt Pcr

scholarly journals Coupling multiplex RT-PCR to a gene chip assay for sensitive and semiquantitative detection of severe acute respiratory syndrome-coronavirus

2004 ◽  
Vol 84 (9) ◽  
pp. 1085-1091 ◽  
Author(s):  
Jyh-Lyh Juang ◽  
Tsan-Chi Chen ◽  
Shih Sheng Jiang ◽  
Chao A Hsiung ◽  
Wei-Chen Chen ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Gene Chip ◽  
Chip Assay ◽  
Rt Pcr

scholarly journals Myopericarditis Associated with COVID-19 in a Pediatric Patient with Kidney Failure Receiving Hemodialysis

Pathogens ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 486
Author(s):  
Marcela Daniela Ionescu ◽  
Mihaela Balgradean ◽  
Catalin Gabriel Cirstoveanu ◽  
Ioana Balgradean ◽  
Loredana Ionela Popa ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Replacement Therapy ◽  
Female Patient ◽  
Pediatric Patient ◽  
Kidney Failure ◽  
Cardiac Tissue ◽  
Pulmonary Involvement ◽  
Rt Pcr ◽  
Acute Pericarditis ◽  
Life Threatening

The outbreak of COVID-19 can be associated with cardiac and pulmonary involvement and is emerging as one of the most significant and life-threatening complications in patients with kidney failure receiving hemodialysis. Here, we report a critically ill case of a 13-year-old female patient with acute pericarditis and bilateral pleurisy, screened positive for SARS-CoV-2 RT-PCR, presented with high fever, frequent dry cough, and dyspnea with tachypnea. COVID-19-induced myopericarditis has been noted to be a complication in patients with concomitant kidney failure with replacement therapy (KFRT). This article brings information in the light of our case experience, suggesting that the direct effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on cardiac tissue was a significant contributor to myopericarditis in our patient. Further studies in this direction are required, as such associations have thus far been reported.

scholarly journals Rapid, sensitive, full genome sequencing of Severe Acute Respiratory Syndrome Virus Coronavirus 2 (SARS-CoV-2)

2020 ◽  
Author(s):  
Clinton R Paden ◽  
Ying Tao ◽  
Krista Queen ◽  
Jing Zhang ◽  
Yan Li ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Sanger Sequencing ◽  
Respiratory Syndrome Virus ◽  
Full Genome ◽  
Miseq Sequencing ◽  
Genomic Information ◽  
Rt Pcr ◽  
Full Genome Sequencing ◽  
High Quality ◽  
Global Pandemic

AbstractSARS-CoV-2 recently emerged, resulting a global pandemic. Rapid genomic information is critical to understanding transmission and pathogenesis. Here, we describe validated protocols for generating high-quality full-length genomes from primary samples. The first employs multiplex RT-PCR followed by MinION or MiSeq sequencing. The second uses singleplex, nested RT-PCR and Sanger sequencing.

scholarly journals RT-PCR for COVID-19: Diagnosis Made Easy

BioMedica ◽  
2020 ◽  
Vol 36 (2S) ◽  
pp. 115-120
Author(s):  
Osheen Sajjad ◽  
Aiman Shahzad ◽  
Saqib Mahmood
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Real Time ◽  
Detection Method ◽  
Current Knowledge ◽  
Detection Methods ◽  
Rt Pcr ◽  
Corona Virus ◽  
Positive Sense ◽  
Affected Person ◽  
Sampling Procedures

<p>Coronavirus disease COVID-19, caused by Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV2), is highly contagious and has been a pandemic since March 2020. The SARS-CoV-2 is an enveloped, single-stranded, positive-sense RNA viruswhich spreadsthrough air droplets by sneezing and coughing from affected person. The diagnosis of the COVID-19 remains a challenge to the scientists since the genome of the SARS-CoV-2 was novel and varying. Various studies have reported the validated procedures for sampling and the detection method of SARS-CoV-2. This mini-review provides a brief introduction of the SARS-CoV-2 features and the current knowledge for the recommended COVID19 detection methods including sampling procedures and real time SARS-CoV-2 genome detection.</p>

scholarly journals A clinical, laboratory, radiological, and microbiologicalstudy of pneumonia associated with covid-19 indicating person-to-person transmission

2021 ◽  
pp. 43832-43834
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Respiratory Tract ◽  
Lower Respiratory Tract ◽  
Clinical Laboratory ◽  
Family Members ◽  
Rt Pcr ◽  
Geographical Regions ◽  
The Family ◽  
Nextgeneration Sequencing ◽  
Novel Coronavirus

Background: Novel coronavirus outbreak that originated in Wuhan, province of China has now been declared as one of the deadliest pandemics inflicting humankind in last hundred years. Method: In the present study, we have inferred the clinical, laboratory, radiological, and microbiological findings of five patients in a family cluster who presented with unexplained pneumonia after coming back from overseas and touchdown right here in India on 1st March 2020 earlier than lockdown and another member of the family who didn’tvisit thiscountry. Results: From March 10, 2020, we enrolled a family of six patients who travelled to SingaporeonJanuary 10th 2020and returned on March 1st 2020. Of six family members who travelled to Singapore, five were recognised as affected with the radical coronavirus (COVID 19). Additionally, one family member, who did not travel to overseas also became infected with the virus post14 days of staying with four of the family members. Five family members (aged 30–55 years) presented with symptoms like fever, upper or lower respiratory tract symptoms, or diarrhoea, or a combination of these 3–6 days after exposure. Phylogenetic evaluation of these five subjects’ RT-PCR amplicons and two full genomes by nextgeneration sequencing presented that this is a novel coronavirus, which is closest to the severe acute respiratory syndrome (SARS)-related coronaviruses. Conclusion: Our findings are steady with person-to-person transmission of this novel coronavirus in hospital (nosocomial) and family settings, and the reports of infected travellers in other geographical regions.

scholarly journals The First Quarter of SARS-CoV-2 Testing: the University of Washington Medicine Experience

2020 ◽  
Vol 58 (8) ◽  
Author(s):  
Alexander L. Greninger ◽  
Keith R. Jerome
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Real Time ◽  
Real Time Pcr ◽  
Medical Center ◽  
Rt Pcr ◽  
University Of Washington ◽  
Clinical Laboratories ◽  
To Come ◽  
The Many ◽  
The University

ABSTRACT In early March 2020, the University of Washington Medical Center clinical virology laboratory became one of the first clinical laboratories to offer testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). When we first began test development in mid-January, neither of us believed there would be more than 2 million confirmed SARS-CoV-2 infections nationwide or that we would have performed more than 150,000 real-time PCR (RT-PCR) tests, with many more to come. This article will be a chronological summary of how we rapidly validated tests for SARS-CoV-2, increased our testing capacity, and addressed the many problems that came up along the way.

scholarly journals Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies

Pathogens ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 1067
Author(s):  
Anwar M. Hashem ◽  
Rowa Y. Alhabbab ◽  
Abdullah Algaissi ◽  
Mohamed A. Alfaleh ◽  
Sharif Hala ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Significant Variation ◽  
High Specificity ◽  
Lateral Flow ◽  
Igg Antibodies ◽  
Rt Pcr ◽  
Standard Methods ◽  
Specific Antibodies ◽  
Time Points

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally. Although several rapid commercial serological assays have been developed, little is known about their performance and accuracy in detecting SARS-CoV-2-specific antibodies in COVID-19 patient samples. Here, we have evaluated the performance of seven commercially available rapid lateral flow immunoassays (LFIA) obtained from different manufacturers, and compared them to in-house developed and validated ELISA assays for the detection of SARS-CoV-2-specific IgM and IgG antibodies in RT-PCR-confirmed COVID-19 patients. While all evaluated LFIA assays showed high specificity, our data showed a significant variation in sensitivity of these assays, which ranged from 0% to 54% for samples collected early during infection (3–7 days post symptoms onset) and from 54% to 88% for samples collected at later time points during infection (8–27 days post symptoms onset). Therefore, we recommend prior evaluation and validation of these assays before being routinely used to detect IgM and IgG in COVID-19 patients. Moreover, our findings suggest the use of LFIA assays in combination with other standard methods, and not as an alternative.

Sign in / Sign up

Export Citation Format

Share Document